Scarica l'app Stockscreener
23.10
2.28%
-0.54
Dopo l'orario di chiusura:
23.10
Precedente Chiudi:
$23.64
Aprire:
$23.31
Volume 24 ore:
644.77K
Relative Volume:
0.90
Capitalizzazione di mercato:
$1.53B
Reddito:
-
Utile/perdita netta:
$-137.95M
Rapporto P/E:
-9.1572
EPS:
-2.5226
Flusso di cassa netto:
$-107.11M
1 W Prestazione:
-1.03%
1M Prestazione:
-16.70%
6M Prestazione:
+15.15%
1 anno Prestazione:
+93.63%
Intervallo 1D:
$22.50
$23.62
Intervallo di 1 settimana:
$22.26
$23.98
Portata 52W:
$10.29
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
23.10 | 1.56B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Iniziato | BofA Securities | Buy |
| 2026-01-29 | Iniziato | Citizens JMP | Mkt Perform |
| 2026-01-08 | Iniziato | BTIG Research | Buy |
| 2025-12-18 | Iniziato | Mizuho | Neutral |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara interim CEO sells 17,500 shares after option exercise - Stock Titan
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight on Bicara stock - Investing.com
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
BCAX Form 4 FilingsBicara Therapeutics SEC Form 4 - Stock Titan
BCAX 424B FilingsBicara Therapeutics SEC 424B - Stock Titan
BCAX 8-K FilingsBicara Therapeutics SEC 8-K - Stock Titan
Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Price, News & Analysis - Kalkine
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com
Boston biotech Bicara signs sublease for Wayfair space - The Business Journals
Bicara (BCAX) Financial Results: Reported EPS Tops Expectations in the Latest Session; Share Move: The Stock Records a 0.50% Decrease in the Current UpdateDividend Cut Risk - vinanet.vn
How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors - webull.com
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Jennifer Larson Net Worth (2026) - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
BMO Capital Initiates Bicara Therapeutics at Outperform - Moomoo
Bicara Therapeutics Initiated at Outperform by BMO Capital - Moomoo
Bicara Therapeutics Inc. (BCAX) Stock Price, News, Quote & History - Yahoo Finance
BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35 - Bitget
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul - Yahoo Finance
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com India
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - Sahm
SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX - MarketBeat
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board - Endpoints News
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX - MarketBeat
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
Janus Henderson Group (BCAX) reports 3.17M Bicara Therapeutics shares in 13G/A - Stock Titan
Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL) - The Globe and Mail
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX) - Yahoo Finance
Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results - webull.com
Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Bicara Therapeutics CEO Claire Mazumdar Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Bicara Therapeutics CFO Ivan Hyep Executes Sale of 12,500 Shares via 10b5-1 Plan - Kalkine Media
Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock - MarketBeat
Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics (BCAX) CFO exercises options, sells 12,500 shares under 10b5-1 plan - Stock Titan
Bicara Therapeutics (BCAX) CEO exercises 10K options and sells 10K shares under plan - Stock Titan
Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares - Stock Titan
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds (NASDAQ:BCAX) - Seeking Alpha
BCAX Maintained by Wells Fargo -- Price Target Raised to $23.00 - GuruFocus
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):